Cargando…
Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H(+)/K(+)-ATPase blocker that is approved in Japan for treatment of GERD. The aim...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780750/ https://www.ncbi.nlm.nih.gov/pubmed/33408859 http://dx.doi.org/10.3892/br.2020.1401 |
_version_ | 1783631561846947840 |
---|---|
author | Tabuchi, Maiko Minami, Hitomi Akazawa, Yuko Ashida, Miwa Hara, Toshihide Ichinose, Kunihiro Kitayama, Moto Hashiguchi, Keiichi Matsushima, Kayoko Yamaguchi, Naoyuki Takeshima, Fuminao Kondo, Hisayoshi Kawakami, Atsushi Nakao, Kazuhiko |
author_facet | Tabuchi, Maiko Minami, Hitomi Akazawa, Yuko Ashida, Miwa Hara, Toshihide Ichinose, Kunihiro Kitayama, Moto Hashiguchi, Keiichi Matsushima, Kayoko Yamaguchi, Naoyuki Takeshima, Fuminao Kondo, Hisayoshi Kawakami, Atsushi Nakao, Kazuhiko |
author_sort | Tabuchi, Maiko |
collection | PubMed |
description | Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H(+)/K(+)-ATPase blocker that is approved in Japan for treatment of GERD. The aim of the present study was to evaluate the efficacy of vonoprazan in SSc-related GERD. The frequency scale for symptoms of GERD (FSSG) scores were collected before and after vonoprazan treatment in 15 SSc patients with GERD. Additionally, endoscopic esophagogastroduodenoscopy was performed in select patients. Conventional proton pump inhibitors or histamine-2 receptor antagonists had been previously administered in 93% (14/15) of the patients. Although the baseline esophagogastroduodenoscopy examination did not show severe erosion in the majority of patients, the mean total FSSG score before vonoprazan treatment was notably high (25.2±10.7) compared to a normal score of <8. After vonoprazan treatment, the FSSG score decreased to 9.6±7.0. The mean improvement rate of the total FSSG, acid reflux and dysmotility scores were 60.8±21.2% (P=0.0004), 67.3±24.8% (P<0.0001) and 55.4±26.0% (P=0.0022), respectively. These results suggest that vonoprazan may be a potentially effective treatment for GERD in patients with SSc. |
format | Online Article Text |
id | pubmed-7780750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-77807502021-01-05 Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease Tabuchi, Maiko Minami, Hitomi Akazawa, Yuko Ashida, Miwa Hara, Toshihide Ichinose, Kunihiro Kitayama, Moto Hashiguchi, Keiichi Matsushima, Kayoko Yamaguchi, Naoyuki Takeshima, Fuminao Kondo, Hisayoshi Kawakami, Atsushi Nakao, Kazuhiko Biomed Rep Articles Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H(+)/K(+)-ATPase blocker that is approved in Japan for treatment of GERD. The aim of the present study was to evaluate the efficacy of vonoprazan in SSc-related GERD. The frequency scale for symptoms of GERD (FSSG) scores were collected before and after vonoprazan treatment in 15 SSc patients with GERD. Additionally, endoscopic esophagogastroduodenoscopy was performed in select patients. Conventional proton pump inhibitors or histamine-2 receptor antagonists had been previously administered in 93% (14/15) of the patients. Although the baseline esophagogastroduodenoscopy examination did not show severe erosion in the majority of patients, the mean total FSSG score before vonoprazan treatment was notably high (25.2±10.7) compared to a normal score of <8. After vonoprazan treatment, the FSSG score decreased to 9.6±7.0. The mean improvement rate of the total FSSG, acid reflux and dysmotility scores were 60.8±21.2% (P=0.0004), 67.3±24.8% (P<0.0001) and 55.4±26.0% (P=0.0022), respectively. These results suggest that vonoprazan may be a potentially effective treatment for GERD in patients with SSc. D.A. Spandidos 2021-02 2020-12-17 /pmc/articles/PMC7780750/ /pubmed/33408859 http://dx.doi.org/10.3892/br.2020.1401 Text en Copyright: © Tabuchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Tabuchi, Maiko Minami, Hitomi Akazawa, Yuko Ashida, Miwa Hara, Toshihide Ichinose, Kunihiro Kitayama, Moto Hashiguchi, Keiichi Matsushima, Kayoko Yamaguchi, Naoyuki Takeshima, Fuminao Kondo, Hisayoshi Kawakami, Atsushi Nakao, Kazuhiko Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title | Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title_full | Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title_fullStr | Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title_full_unstemmed | Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title_short | Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
title_sort | use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780750/ https://www.ncbi.nlm.nih.gov/pubmed/33408859 http://dx.doi.org/10.3892/br.2020.1401 |
work_keys_str_mv | AT tabuchimaiko useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT minamihitomi useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT akazawayuko useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT ashidamiwa useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT haratoshihide useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT ichinosekunihiro useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT kitayamamoto useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT hashiguchikeiichi useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT matsushimakayoko useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT yamaguchinaoyuki useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT takeshimafuminao useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT kondohisayoshi useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT kawakamiatsushi useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease AT nakaokazuhiko useofvonoprazanformanagementofsystemicsclerosisrelatedgastroesophagealrefluxdisease |